| Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 |
|---|---|---|---|---|---|
Gross Sales | 2,624.4 | 2,571.7 | 2,198.5 | 1,846.1 | 1,525.7 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,624.4 | 2,571.7 | 2,198.5 | 1,846.1 | 1,525.7 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 84.9 | 74.5 | 48.1 | 38.1 | 46.2 |
Total Income | 2,709.3 | 2,646.2 | 2,246.6 | 1,884.2 | 1,571.9 |
Total Expenditure | 1,926.2 | 1,885.3 | 1,578.2 | 1,331 | 1,069.3 |
PBIDT | 783.1 | 760.9 | 668.4 | 553.2 | 502.6 |
Interest | 37.2 | 34.3 | 34.8 | 18.5 | 21.1 |
PBDT | 745.9 | 726.6 | 633.6 | 534.7 | 481.5 |
Depreciation | 326.5 | 314.8 | 270.9 | 229.4 | 204.5 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 91.5 | 80.6 | 63.5 | 57.3 | 32.7 |
Deferred Tax | 15 | 9.8 | 13.6 | 0 | 0 |
Reported Profit After Tax | 312.9 | 321.4 | 285.6 | 248 | 244.3 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 312.9 | 321.4 | 285.6 | 248 | 244.3 |
Extra-ordinary Items | 23.87 | -8.66 | 0 | -24.94 | 0 |
Adjusted Profit After Extra-ordinary item | 289.03 | 330.06 | 285.6 | 272.94 | 244.3 |
EPS (Unit Curr.) | 7.79 | 8.01 | 7.12 | 6.12 | 6.14 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 402.5 | 402 | 401.4 | 400.8 | 400 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 29.83 | 29.58 | 30.4 | 29.96 | 32.94 |
PBDTM(%) | 28.42 | 28.25 | 28.81 | 28.96 | 31.55 |
PATM(%) | 11.92 | 12.49 | 12.99 | 13.43 | 16.01 |
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
